secwatch / observer
8-K filed February 6, 2025, 6:59 PM ET ticker TERN CIK 0001831363
leadership confidence high sentiment neutral materiality 0.60

Terns Pharmaceuticals CFO Mark Vignola Departs; CEO Burroughs Takes Interim CFO Role

Terns Pharmaceuticals, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change (interim)

Amy Burroughs

Principal Financial Officer
TERN · Terns Pharmaceuticals, Inc.
Effective
2025-02-01
Filed
February 6, 2025, 6:59 PM ET
Effective as of the Vignola Separation Date, Amy Burroughs, the Company’s Chief Executive Officer, has assumed the role of principal financial officer and David Strauss, the Company’s Vice President of Finance and Controller, has assumed the role of principal accounting officer of the Company, in each case on an interim basis.
Departed

Mark Vignola

Chief Financial Officer
TERN · Terns Pharmaceuticals, Inc.
Effective
2025-02-01
Successor
Amy Burroughs
Filed
February 6, 2025, 6:59 PM ET
On February 1, 2025, pursuant to, and subject to the terms of, the Vignola Transition Agreement, Mr. Vignola confirmed that his separation from employment was effective as of February 1, 2025 (the “Vignola Separation Date”) and resigned as of the Vignola Separation Date from all officer and director positions at the Company, the Subsidiary and any other subsidiary or affiliate.
Role change (interim)

David Strauss

Principal Accounting Officer
TERN · Terns Pharmaceuticals, Inc.
Effective
2025-02-01
Filed
February 6, 2025, 6:59 PM ET
Effective as of the Vignola Separation Date, Amy Burroughs, the Company’s Chief Executive Officer, has assumed the role of principal financial officer and David Strauss, the Company’s Vice President of Finance and Controller, has assumed the role of principal accounting officer of the Company, in each case on an interim basis.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Burroughs changed role as Principal Financial Officer at Terns Pharmaceuticals, Inc..

Action
assumed
Role
Principal Financial Officer
Exact text from the filing
Effective as of the Vignola Separation Date, Amy Burroughs, the Company’s Chief Executive Officer, has assumed the role of principal financial officer and David Strauss, the Company’s Vice President of Finance and Controller, has assumed the role of principal accounting officer of the Company, in each case on an interim basis.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Vignola resigned as Chief Financial Officer at Terns Pharmaceuticals, Inc..

Action
resigned
Role
Chief Financial Officer
Exact text from the filing
On February 1, 2025, pursuant to, and subject to the terms of, the Vignola Transition Agreement, Mr. Vignola confirmed that his separation from employment was effective as of February 1, 2025 (the “Vignola Separation Date”) and resigned as of the Vignola Separation Date from all officer and director positions at the Company, the Subsidiary and any other subsidiary or affiliate.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

David Strauss changed role as Principal Accounting Officer at Terns Pharmaceuticals, Inc..

Action
assumed
Role
Principal Accounting Officer
Exact text from the filing
Effective as of the Vignola Separation Date, Amy Burroughs, the Company’s Chief Executive Officer, has assumed the role of principal financial officer and David Strauss, the Company’s Vice President of Finance and Controller, has assumed the role of principal accounting officer of the Company, in each case on an interim basis.
View on SEC.gov

Terns Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR
accession 0000950170-25-015501
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.